Distinctive trade mark treatment for medicines and incomplete duty reasoning require fresh adjudication of excise liability.

Neomycin Sulphate Capsules were treated as Patent & Proprietary Medicine under Item 14E because the label and design, read as a whole, operated as a distinctive trade-connected symbol identifying the manufacturer. The discussion applies the test that a mark or monogram must distinguish the medicine from others in the market. It also notes that the demand aspect required fresh consideration because several assessee pleas were not examined, including invoicing, alleged third-party supply, exclusions from clearance, exemption eligibility, and the basis of duty calculation. A proper duty work-sheet and full hearing were required before any final adjudication.

---

---

Issues: (i) Whether Neomycin Sulphate Capsules bearing the labels and design described in the order were Patent & Proprietary Medicine under Item 14E of the erstwhile Central Excise Tariff; (ii) Whether the adjudication order was liable to be set aside and the matter remanded for fresh consideration of the appellants' pleas and the duty calculation.

Issue (i): Whether Neomycin Sulphate Capsules bearing the labels and design described in the order were Patent & Proprietary Medicine under Item 14E of the erstwhile Central Excise Tariff.

Analysis: The label contained an inverted triangle with a mark inside and also three coloured rectangles arranged in a row. Taken together, these features constituted a symbol and monogram used in relation to the medicines for indicating a connection in the course of trade between the goods and the manufacturer. Applying the test of whether the mark or design was distinctive so as to distinguish the medicines from those of others, the goods answered the description of Patent & Proprietary Medicine.

Conclusion: The classification under Item 14E was upheld against the assessee.

Issue (ii): Whether the adjudication order was liable to be set aside and the matter remanded for fresh consideration of the appellants' pleas and the duty calculation.

Analysis: The order did not deal with the appellants' pleas regarding invoices marked 'A', alleged supply through a Bombay firm, exclusion of clearances to the Sales Office against gate passes, eligibility to exemption and the option between exemptions. The calculation basis for duty was also not supplied. As these matters required examination and hearing, the order suffered from non-application of mind on the demand aspect.

Conclusion: The matter was remanded to the Collector for fresh adjudication after considering all pleas and supplying the duty work-sheet to the appellants.

Final Conclusion: The classification of the capsules as Patent & Proprietary Medicine was sustained, but the duty demand and connected issues were sent back for reconsideration in accordance with law.

Ratio Decidendi: A medicine bears a distinctive mark for tariff purposes when the label or design, taken as a whole, functions as a trade-connected symbol identifying the manufacturer; where material pleas affecting duty liability are not examined and the duty basis is undisclosed, fresh adjudication is required.

---